237 related articles for article (PubMed ID: 29940415)
21. Serological Evidence of Filovirus Infection in Nonhuman Primates in Zambia.
Changula K; Simulundu E; Lombe BP; Nakayama E; Miyamoto H; Takahashi Y; Sawa H; Simukonda C; Hang'ombe BM; Takada A
Viruses; 2021 Jun; 13(7):. PubMed ID: 34209295
[TBL] [Abstract][Full Text] [Related]
22. Immune response to filovirus infections.
Ignatyev GM
Curr Top Microbiol Immunol; 1999; 235():205-17. PubMed ID: 9893385
[No Abstract] [Full Text] [Related]
23. Seroepidemiological Prevalence of Multiple Species of Filoviruses in Fruit Bats (Eidolon helvum) Migrating in Africa.
Ogawa H; Miyamoto H; Nakayama E; Yoshida R; Nakamura I; Sawa H; Ishii A; Thomas Y; Nakagawa E; Matsuno K; Kajihara M; Maruyama J; Nao N; Muramatsu M; Kuroda M; Simulundu E; Changula K; Hang'ombe B; Namangala B; Nambota A; Katampi J; Igarashi M; Ito K; Feldmann H; Sugimoto C; Moonga L; Mweene A; Takada A
J Infect Dis; 2015 Oct; 212 Suppl 2():S101-8. PubMed ID: 25786916
[TBL] [Abstract][Full Text] [Related]
24. Challenges, progress, and opportunities: proceedings of the filovirus medical countermeasures workshop.
Hirschberg R; Ward LA; Kilgore N; Kurnat R; Schiltz H; Albrecht MT; Christopher GW; Nuzum E
Viruses; 2014 Jul; 6(7):2673-97. PubMed ID: 25010768
[TBL] [Abstract][Full Text] [Related]
25. Generation and Selection of a Panel of Pan-Filovirus Single-Chain Antibodies using Cell-Free Ribosome Display.
Kunamneni A; Clarke EC; Ye C; Bradfute SB; Durvasula R
Am J Trop Med Hyg; 2019 Jul; 101(1):198-206. PubMed ID: 31074409
[TBL] [Abstract][Full Text] [Related]
26. Filovirus emergence and vaccine development: a perspective for health care practitioners in travel medicine.
Sarwar UN; Sitar S; Ledgerwood JE
Travel Med Infect Dis; 2011 May; 9(3):126-34. PubMed ID: 21208830
[TBL] [Abstract][Full Text] [Related]
27. Identity and validity of conserved B cell epitopes of filovirus glycoprotein: towards rapid diagnostic testing for Ebola and possibly Marburg virus disease.
Babirye P; Musubika C; Kirimunda S; Downing R; Lutwama JJ; Mbidde EK; Weyer J; Paweska JT; Joloba ML; Wayengera M
BMC Infect Dis; 2018 Oct; 18(1):498. PubMed ID: 30285648
[TBL] [Abstract][Full Text] [Related]
28. Advances in virus-like particle vaccines for filoviruses.
Warfield KL; Aman MJ
J Infect Dis; 2011 Nov; 204 Suppl 3(Suppl 3):S1053-9. PubMed ID: 21987741
[TBL] [Abstract][Full Text] [Related]
29. Cell Attachment Domains of the Porcine Epidemic Diarrhea Virus Spike Protein Are Key Targets of Neutralizing Antibodies.
Li C; Li W; Lucio de Esesarte E; Guo H; van den Elzen P; Aarts E; van den Born E; Rottier PJM; Bosch BJ
J Virol; 2017 Jun; 91(12):. PubMed ID: 28381581
[TBL] [Abstract][Full Text] [Related]
30. Protection against filovirus infection: virus-like particle vaccines.
Yang C; Ye L; Compans RW
Expert Rev Vaccines; 2008 Apr; 7(3):333-44. PubMed ID: 18393603
[TBL] [Abstract][Full Text] [Related]
31. Quantification of Filovirus Glycoprotein-Specific Antibodies.
Furuyama W; Miyamoto H; Yoshida R; Takada A
Methods Mol Biol; 2017; 1628():309-320. PubMed ID: 28573631
[TBL] [Abstract][Full Text] [Related]
32. Filovirus-like particles as vaccines and discovery tools.
Warfield KL; Swenson DL; Demmin G; Bavari S
Expert Rev Vaccines; 2005 Jun; 4(3):429-40. PubMed ID: 16026254
[TBL] [Abstract][Full Text] [Related]
33. Correlates of immunity to filovirus infection.
Bradfute SB; Bavari S
Viruses; 2011 Jul; 3(7):982-1000. PubMed ID: 21994766
[TBL] [Abstract][Full Text] [Related]
34. Complete protection of the BALB/c and C57BL/6J mice against Ebola and Marburg virus lethal challenges by pan-filovirus T-cell epigraph vaccine.
Rahim MN; Wee EG; He S; Audet J; Tierney K; Moyo N; Hannoun Z; Crook A; Baines A; Korber B; Qiu X; Hanke T
PLoS Pathog; 2019 Feb; 15(2):e1007564. PubMed ID: 30817809
[TBL] [Abstract][Full Text] [Related]
35. Filoviruses and the balance of innate, adaptive, and inflammatory responses.
Mohamadzadeh M; Chen L; Olinger GG; Pratt WD; Schmaljohn AL
Viral Immunol; 2006; 19(4):602-12. PubMed ID: 17201655
[TBL] [Abstract][Full Text] [Related]
36. The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific Antibodies.
Brinkmann C; Nehlmeier I; Walendy-Gnirß K; Nehls J; González Hernández M; Hoffmann M; Qiu X; Takada A; Schindler M; Pöhlmann S
J Virol; 2016 Dec; 90(24):11075-11086. PubMed ID: 27707924
[TBL] [Abstract][Full Text] [Related]
37. [Innate immunity evasion mechanisms of filoviruses].
Martin B; Decroly É
Med Sci (Paris); 2018; 34(8-9):671-677. PubMed ID: 30230452
[TBL] [Abstract][Full Text] [Related]
38. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease.
Dye JM; Herbert AS; Kuehne AI; Barth JF; Muhammad MA; Zak SE; Ortiz RA; Prugar LI; Pratt WD
Proc Natl Acad Sci U S A; 2012 Mar; 109(13):5034-9. PubMed ID: 22411795
[TBL] [Abstract][Full Text] [Related]
39. Filovirus vaccines: what challenges are left?
Bukreyev A; Collins PL
Expert Rev Vaccines; 2010 Jan; 9(1):5-8. PubMed ID: 20021298
[No Abstract] [Full Text] [Related]
40. Filovirus-reactive antibodies in humans and bats in Northeast India imply zoonotic spillover.
Dovih P; Laing ED; Chen Y; Low DHW; Ansil BR; Yang X; Shi Z; Broder CC; Smith GJD; Linster M; Ramakrishnan U; Mendenhall IH
PLoS Negl Trop Dis; 2019 Oct; 13(10):e0007733. PubMed ID: 31671094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
